• Ja-An Lin and Pei He.
• Department of Biostatistics, The University of North Carolina at Chapel Hill, 170 Rosenau Hall, Chapel Hill, NC, USA.
• Br. Med. Bull. 2015 Jun 1; 114 (1): 17-27.

IntroductionRecently, new clinical trial designs involving biomarkers have been studied and proposed in cancer clinical research, in the hope of incorporating the rapid growing basic research into clinical practices.Sources Of DataJournal articles related to various biomarkers and their role in cancer clinical trial, articles and books about statistical issues in trial design, and regulatory website, documents, and guidance for submission of targeted cancer therapies.Areas Of AgreementThe drug development process involves four phases. The confirmatory Phase III is essential in regulatory approval of a special treatment.Areas Of ControversyRegulatory agency has restrictions on confirmatory trials 'using adaptive designs'. No rule of thumb to pick the most appropriate design for biomarker-related trials.Growing PointsStatistical issues to solve in new designs. Regulatory acceptance of the 'newly proposed trial designs'.Areas Timely For Developing ResearchBiomarker-related trial designs that can resolve the statistical issues and satisfy the regulatory requirement.© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

17 keywords...

hide…